using biomarkers to predict response to combination therapies in braf-mutant melanoma
Published 8 years ago • 72 plays • Length 2:10Download video MP4
Download video MP3
Similar videos
-
1:06
evaluating the suitability of checkpoint inhibitors with biomarkers in patients with melanoma
-
2:58
the importance of biomarkers to optimize treatment with immunotherapy for melanoma
-
5:16
promising biomarkers to select patients for checkpoint inhibitor therapy in melanoma
-
3:08
os rates and prognostic categories for braf-mutated melanoma when treated with combination therapy
-
2:40
how can biomarkers help predict patient reponse in melanoma
-
9:24
anti-pd1 monotherapy or combination with ipi after braf/mek inhibitors in braf-mutant melanoma
-
1:30
what to do with braf-mutant melanoma patients who have a poor prognosis?
-
27:28
advances in therapy for braf-mutant melanoma
-
2:10
combined treatment with braf and mek inhibitors in metastatic melanomas with braf mutations
-
4:05
vemurafenib and cobimetinib in patients with braf-mutated melanoma
-
2:25
biomarker analysis of cobrim: combined vemurafenib and cobimetinib for braf-mutated melanoma
-
33:17
evaluating biomarkers for response to neoadjuvant immune checkpoint blockade..
-
24:18
immunotherapy biomarkers and patient selection
-
1:17
treatment selection for stage iii braf-mutant melanoma
-
1:14
exploring treatment options after til therapy in melanoma: biomarkers & regimen selection
-
1:19
dr. hamid on using biomarkers for immunotherapy in melanoma
-
1:02:45
biomarkers in breast cancer: current practice, opportunities and unmet needs
-
0:59
the success of the dabrafenib and trametinib combination in braf-mutated melanoma
-
2:29
braf mutated melanoma: targeted or immunotherapy?